Anthony Y. Sun Sells 64,562 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock

Share on StockTwits

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) CEO Anthony Y. Sun sold 64,562 shares of the business’s stock in a transaction that occurred on Monday, April 5th. The stock was sold at an average price of $43.43, for a total value of $2,803,927.66. Following the transaction, the chief executive officer now owns 1,743,479 shares in the company, valued at approximately $75,719,292.97. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of ZNTL stock opened at $41.07 on Thursday. The business’s fifty day moving average is $42.42 and its 200-day moving average is $43.36. Zentalis Pharmaceuticals, Inc. has a 1 year low of $23.25 and a 1 year high of $61.29.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Wednesday, March 24th. The company reported ($1.01) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.06). As a group, research analysts expect that Zentalis Pharmaceuticals, Inc. will post -4.69 earnings per share for the current year.

ZNTL has been the subject of several recent analyst reports. HC Wainwright boosted their price objective on shares of Zentalis Pharmaceuticals from $43.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, April 1st. Wedbush initiated coverage on Zentalis Pharmaceuticals in a report on Tuesday, January 19th. They set an “outperform” rating and a $65.00 target price on the stock. Finally, Morgan Stanley raised their target price on Zentalis Pharmaceuticals from $50.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, December 16th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Zentalis Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $53.38.

Several institutional investors have recently bought and sold shares of the company. Pacer Advisors Inc. bought a new position in Zentalis Pharmaceuticals during the fourth quarter valued at about $45,000. Penserra Capital Management LLC acquired a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at approximately $48,000. JPMorgan Chase & Co. grew its stake in shares of Zentalis Pharmaceuticals by 23.6% in the third quarter. JPMorgan Chase & Co. now owns 4,297 shares of the company’s stock worth $144,000 after acquiring an additional 820 shares during the last quarter. Strs Ohio increased its holdings in shares of Zentalis Pharmaceuticals by 25.9% during the 4th quarter. Strs Ohio now owns 3,400 shares of the company’s stock worth $176,000 after purchasing an additional 700 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in Zentalis Pharmaceuticals by 6.8% during the third quarter. The Manufacturers Life Insurance Company now owns 6,337 shares of the company’s stock valued at $207,000 after acquiring an additional 402 shares during the period. Institutional investors and hedge funds own 67.13% of the company’s stock.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of various cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of advanced or metastatic breast cancer.

See Also: Accumulation/Distribution

Insider Buying and Selling by Quarter for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with's FREE daily email newsletter.